MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA. It has been studied as a metabolic regulator with roles in insulin sensitivity, exercise capacity, and aging-related metabolic decline. Most of the data sits in animal models, with limited human evidence.
Like BPC-157 and TB-500, MOTS-c has become a popular research peptide in the longevity and biohacking community. The PCAC and FDA's Section 503A bulks list categorization is in progress; state medical board enforcement actions have included it. ProPublica's 2026 reporting on the FDA's 2023 effective ban listed MOTS-c among the 19 injectable peptides at issue.
Clinical evidence in humans is preliminary. Stories here cover regulatory action and any progress toward registered trials.
A 2026 Frontiers in Aging review consolidates the case for therapeutic peptides as gerontology agents, mapping mechanisms across mitochondrial-derived peptides (MOTS-c, humanin), thymic peptides (thymosin alpha-1), wound-and-tissue-repair peptides (BPC-157, TB-500), copper peptides (GHK-Cu), and growth-hormone secretagogues (CJC-1295, ipamorelin). The review frames the longevity peptide field as a clinical category that now sits alongside GLP-1 metabolic medicine — driven by Hims & Hers' 2026 longevity-specialty launch, Drexel's May 5 Q&A on peptide popularity, and the FDA Category 2 removal of 12 peptides on April 22. The piece also flags that BPC-157, TB-500, and most wellness peptides still lack published human RCTs, with clinical use largely based on case reports and preclinical mechanistic rationale.
Effective April 22, BPC-157, TB-500, Semax, Epitalon, MOTS-c and seven other peptides were formally removed from the FDA's 503A Category 2 significant-safety-concerns list after original nominators withdrew submissions. The FDA Pharmacy Compounding Advisory Committee will meet July 23-24 to decide whether to add these peptides to the 503A bulks list, which would restore legal compounding under prescription.
A Bloomberg opinion piece published April 21 argues that the FDA's planned July 23-24 PCAC review of seven peptides (BPC-157, MOTS-c, KPV, among others) and RFK Jr.'s broader push to reclassify 14 of 19 Category 2 peptides doesn't give consumers the evidence-based safety and efficacy data they need. The piece frames the ongoing compounding debate as a consumer-protection gap that clinical trial evidence — not political reclassification — should fill.
The UK's MHRA is investigating peptide clinics promoting BPC-157, MOTS-C, and Cortexin with unproven claims. Making medicinal claims classifies these products as medicines under UK law.
Health Secretary Kennedy announced on Joe Rogan's podcast that the FDA will soon reclassify about 14 peptides currently restricted from compounding pharmacies, aiming to curb gray-market sourcing.